High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma By Ogkologos - August 20, 2026 83 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATRix/IELSG43 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR Improving cancer care for the LGBTQ+ community July 26, 2021 Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... July 29, 2025 Makeup Artist Gives Breast Cancer Survivors Free Makeovers January 6, 2021 Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 Load more HOT NEWS Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive... Obesity May Help Tumors Survive and Grow, Mouse Study Suggests Cancer in My Community: Obstacles to Caring for People With Cancer...
